---
title: "Imunon regains Nasdaq minimum bid price compliance"
url: "https://aibio.space/news/imunon-regains-nasdaq-minimum-bid-price-compliance-after-hearings/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-08-28"
section: "Listings"
tickers: "NASDAQ:IMNN"
source: "https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/ex99-1.htm"
summary: "The Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent"
---

By the aibio.space news desk.

Sources

- [Imunon, Inc. 8-K (2025-08-28)](https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/ex99-1.htm)

[IMNN](https://aibio.space/companies/imunon/)

2025-08-28

# Imunon regains Nasdaq minimum bid price compliance after hearings panel confirmation

Tickers [IMNN](https://aibio.space/companies/imunon/)

The Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent 15% stock dividend.

## Key facts

- **Company**: Imunon, Inc. (NASDAQ: IMNN)

- **News type**: Listings

- **Primary source**: [Imunon, Inc. 8-K (2025-08-28)](https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/ex99-1.htm)

*The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Imunon, Inc. said it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The company announced the news on August 28, 2025, after confirmation from the Nasdaq Hearings Panel. A hearings panel is the Nasdaq body that reviews a company's case when it faces delisting. The bid price rule requires a listed stock to trade at or above a set minimum price.

As a result, Imunon said its common stock will continue uninterrupted trading on The Nasdaq Capital Market.

Chief executive Stacy Lindborg said the listing news coincides with a recent 15% stock dividend paid to shareholders of record as of August 7, 2025. A stock dividend pays holders in new shares rather than cash. "Having regained compliance with Nasdaq's minimum bid price listing requirement, investors in IMUNON's stock are assured of efficient liquidity as provided by the exchange," she said.

Imunon is in Phase 3 development of IMNN-001, a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. The company said it has started its Phase 3 OVATION 3 trial in North America.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

IMNN

Imunon, Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/imunon-regains-nasdaq-minimum-bid-price-compliance-after-hearings/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Imunon regains Nasdaq minimum bid price compliance", 2025-08-28, https://aibio.space/news/imunon-regains-nasdaq-minimum-bid-price-compliance-after-hearings/